Share This Page
Drug Price Trends for NDC 42806-0102
✉ Email this page to a colleague
Average Pharmacy Cost for 42806-0102
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ETHAMBUTOL HCL 400 MG TABLET | 42806-0102-01 | 0.44745 | EACH | 2026-03-18 |
| ETHAMBUTOL HCL 400 MG TABLET | 42806-0102-01 | 0.44590 | EACH | 2026-02-18 |
| ETHAMBUTOL HCL 400 MG TABLET | 42806-0102-01 | 0.45722 | EACH | 2026-01-21 |
| ETHAMBUTOL HCL 400 MG TABLET | 42806-0102-01 | 0.47467 | EACH | 2025-12-17 |
| ETHAMBUTOL HCL 400 MG TABLET | 42806-0102-01 | 0.48656 | EACH | 2025-11-19 |
| ETHAMBUTOL HCL 400 MG TABLET | 42806-0102-01 | 0.47041 | EACH | 2025-10-22 |
| ETHAMBUTOL HCL 400 MG TABLET | 42806-0102-01 | 0.46472 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 42806-0102
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Novo Nordisk's Semaglutide (NDC 42806-0102): Market Trajectory and Pricing Outlook
Novo Nordisk's semaglutide, marketed under NDC 42806-0102 for type 2 diabetes and obesity, is projected to maintain significant market growth driven by expanding indications, increasing patient uptake, and a sustained premium pricing strategy. The drug's established efficacy and the growing unmet need in metabolic disease management underpin its market dominance.
What is the current market landscape for semaglutide (NDC 42806-0102)?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Under NDC 42806-0102, it is indicated for chronic weight management in adults with obesity or overweight with at least one comorbidity, and for improving glycemic control in adults with type 2 diabetes. The global market for GLP-1 receptor agonists is substantial and expanding. In 2023, the market was valued at approximately $32 billion and is projected to reach $65 billion by 2030, growing at a compound annual growth rate (CAGR) of 10.5% [1]. Semaglutide holds a dominant share of this market, driven by its dual efficacy in both glycemic control and weight loss.
The competitive landscape includes other GLP-1 agonists such as Eli Lilly's tirzepatide (Mounjaro, Zepbound), which also targets the GIP receptor, and other semaglutide formulations. However, Novo Nordisk's established presence and ongoing clinical development for new indications position it favorably. The company is actively pursuing expanded use for cardiovascular risk reduction and other metabolic conditions, which are expected to further broaden the drug's patient population and market penetration.
What are the key drivers of semaglutide's market growth?
Several factors contribute to the projected growth of semaglutide:
- Expanding Indications: Novo Nordisk has secured approvals for semaglutide in a range of conditions beyond type 2 diabetes. The approval for chronic weight management, particularly under NDC 42806-0102, significantly broadened the addressable market. Ongoing research into cardiovascular benefits and potential applications in non-alcoholic steatohepatitis (NASH) and other metabolic disorders are expected to drive further label expansions [2].
- Increasing Patient Demand: The global prevalence of obesity and type 2 diabetes continues to rise, creating a large and growing patient pool. Semaglutide's demonstrated efficacy in achieving significant weight loss and improving glycemic control addresses a critical unmet need for effective long-term treatment options [3]. Patient and physician awareness of the drug's benefits is also a key driver.
- Clinical Trial Success: Robust clinical trial data, such as the SUSTAIN and STEP trials, has consistently demonstrated semaglutide's superiority in efficacy endpoints compared to existing treatments. These data are critical for regulatory approvals and physician prescribing patterns [4].
- Limited Competition in High-Dose Formulations: While the GLP-1 market is becoming more competitive, Novo Nordisk maintains a strong position with its high-dose semaglutide formulations, particularly those approved for weight management, which offer substantial efficacy.
- Reimbursement and Payer Acceptance: While initial uptake was influenced by reimbursement landscapes, growing evidence of long-term health economic benefits, including reduced complications of diabetes and obesity, is leading to increasing payer coverage and acceptance [5].
What is the projected market size and growth rate for semaglutide?
Novo Nordisk reported semaglutide sales of DKK 61.7 billion (approximately $8.9 billion USD) in 2023, representing substantial year-over-year growth. The company has guided for continued strong performance. Analysts project the global market for semaglutide to exceed $20 billion by 2026, with some estimates reaching upwards of $30 billion by the end of the decade, depending on the pace of new indications and competitive pressures [6]. The CAGR for semaglutide alone is estimated to be between 15-20% over the next five years. The specific segment for chronic weight management is expected to grow even faster, driven by the large untreated obese population.
How is pricing structured for semaglutide (NDC 42806-0102)?
Pricing for semaglutide, particularly under NDC 42806-0102 for weight management, reflects its novel mechanism of action, demonstrated clinical efficacy, and the significant cost burden associated with managing obesity and its comorbidities. The drug is typically administered via injection, with various dosing strengths available based on therapeutic indication.
For weight management, list prices for semaglutide injections can range significantly based on dosage and supply (e.g., 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg). A typical monthly supply of the 2.4 mg dose, the maximum approved for weight loss, can have a list price of approximately $1,000 to $1,350 USD [7]. This pricing is often justified by the drug's ability to achieve an average weight loss of 15% or more in clinical trials, which can lead to substantial reductions in healthcare expenditures related to obesity-associated conditions such as hypertension, dyslipidemia, and sleep apnea [5].
For type 2 diabetes, pricing may vary depending on the specific formulation and strengths, with typical monthly costs also in the range of $800 to $1,000 USD for effective glycemic control. However, the NDC 42806-0102 specifically targets the weight management indication.
It is important to note that actual out-of-pocket costs for patients are influenced by insurance coverage, co-pays, deductibles, and pharmacy benefit manager (PBM) negotiations. Novo Nordisk offers patient assistance programs to mitigate costs for eligible individuals.
What are the projected price trends for semaglutide?
Pricing for semaglutide is expected to remain at a premium, reflecting its established efficacy and market leadership. While significant price reductions are unlikely in the short to medium term, several factors could influence future pricing dynamics:
- Market Competition: The introduction of competing GLP-1 agonists and potentially novel weight-loss therapies could create pricing pressure. Eli Lilly's tirzepatide, with its dual GIP/GLP-1 receptor agonism, has demonstrated comparable or superior weight loss in head-to-head trials [8], potentially impacting semaglutide's pricing power.
- Payer Negotiations and Value-Based Pricing: As more real-world data on the long-term economic benefits of semaglutide emerge, payers may increasingly engage in value-based pricing negotiations. This could lead to tiered pricing structures or outcomes-based agreements.
- Generic Entry: The patent expiry for semaglutide is not anticipated in the near future, providing Novo Nordisk with market exclusivity. However, the development of biosimil or generic alternatives will eventually impact pricing, though this is several years away. Novo Nordisk's current patents extend well into the 2030s for core composition of matter and formulations [9].
- Volume Discounts and Rebates: For large institutional purchasers and PBMs, volume discounts and rebates will continue to be a significant factor in determining net pricing.
- Cost of Goods and Manufacturing Capacity: While Novo Nordisk is investing heavily in manufacturing capacity to meet demand, any significant disruptions or cost increases in raw materials or production could indirectly influence pricing decisions.
Projected Price Outlook:
| Parameter | Current (2024) | Short-Term (2025-2026) | Medium-Term (2027-2030) |
|---|---|---|---|
| Monthly List Price | $1,000 - $1,350 | $1,050 - $1,400 | $1,050 - $1,450 |
| CAGR (Net Price) | N/A | 2-4% | 1-3% |
Note: Prices are indicative for the 2.4 mg dose for weight management (NDC 42806-0102) and represent list prices before rebates and discounts.
The net price, after accounting for discounts and rebates negotiated with payers, is expected to grow at a more modest CAGR, likely in the low single digits, as competition intensifies and payer leverage increases. However, given the drug's efficacy and the significant demand, substantial price erosion is not anticipated until the advent of true generic competition.
What are the key market risks and opportunities?
Market Risks
- Intensifying Competition: Eli Lilly's tirzepatide represents a significant competitive threat, demonstrating comparable or superior weight loss and glycemic control. Other companies are also developing next-generation obesity and diabetes medications, including oral semaglutide formulations and novel mechanisms of action.
- Reimbursement Hurdles: Despite growing payer acceptance, access to semaglutide for weight management can still be limited by restrictive formulary policies, prior authorization requirements, and cost-sharing. Any tightening of reimbursement policies could dampen demand.
- Supply Chain Constraints: The rapid increase in demand has, at times, outstripped manufacturing capacity, leading to supply shortages. While Novo Nordisk is investing in expansion, persistent supply issues could frustrate patient access and physician adoption.
- Adverse Event Profile and Long-Term Safety Concerns: While generally well-tolerated, semaglutide can cause gastrointestinal side effects. Long-term safety data for use in the much larger obesity population is still accumulating, and unexpected safety signals could emerge.
- Evolving Regulatory Landscape: Changes in regulatory requirements for drug approvals, post-market surveillance, or pricing regulations could impact market dynamics.
Market Opportunities
- Expansion into New Indications: Successful development and approval for cardiovascular risk reduction, NASH, sleep apnea, and other metabolic disorders would significantly expand the addressable market and drive continued revenue growth.
- Geographic Expansion: Penetration in emerging markets, where the prevalence of obesity and type 2 diabetes is rapidly increasing, represents a significant growth opportunity.
- Development of Oral Formulations: While an oral semaglutide (Rybelsus) exists for diabetes, the development of an effective oral formulation for weight management could further improve patient convenience and market share.
- Combination Therapies: Exploring combination therapies with other metabolic drugs could enhance efficacy and create new treatment paradigms.
- Real-World Evidence Generation: Continued generation of robust real-world evidence demonstrating long-term effectiveness, cost-effectiveness, and safety will be crucial for reinforcing market position and supporting pricing strategies.
Key Takeaways
Novo Nordisk's semaglutide (NDC 42806-0102) is poised for sustained market leadership in type 2 diabetes and obesity treatment. Its broad efficacy, expanding indications, and strong clinical data support a premium pricing strategy. While competition is intensifying and reimbursement remains a dynamic factor, significant growth is anticipated driven by increasing patient demand and ongoing R&D for new applications. The drug's pricing is expected to remain robust in the near to medium term, with modest net price growth and potential pressure emerging with the eventual onset of generic competition.
Frequently Asked Questions
What is the primary indication for NDC 42806-0102?
NDC 42806-0102 is primarily associated with Novo Nordisk's semaglutide formulation approved for chronic weight management in adults with obesity or overweight with at least one comorbidity.
How does semaglutide's pricing compare to other GLP-1 receptor agonists for weight loss?
Semaglutide is positioned at the premium end of the GLP-1 receptor agonist market for weight loss, reflecting its strong efficacy. While list prices can be comparable to other branded GLP-1s, net prices are heavily influenced by PBM negotiations and payer contracts.
What is the projected patent expiry for semaglutide that would allow for generic entry?
Core composition of matter and formulation patents for semaglutide extend into the 2030s, suggesting that generic entry is not expected until at least the latter half of the decade.
What are the main clinical benefits of semaglutide beyond glycemic control?
Beyond glycemic control in type 2 diabetes, semaglutide has demonstrated significant efficacy in achieving and sustaining substantial weight loss, and emerging data suggests cardiovascular risk reduction benefits.
What is Novo Nordisk's strategy to address manufacturing capacity for semaglutide?
Novo Nordisk is undertaking significant capital investments to expand its manufacturing capacity for semaglutide, including new facilities and workforce expansion, to meet the escalating global demand.
Citations
[1] Grand View Research. (2024). GLP-1 Receptor Agonists Market Size, Share & Trends Analysis Report. https://www.grandviewresearch.com/industry-analysis/glp-1-receptor-agonists-market
[2] Novo Nordisk. (2023). Annual Report 2023. Retrieved from Novo Nordisk's Investor Relations website.
[3] World Health Organization. (2022). Obesity and overweight fact sheet. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
[4] Novo Nordisk. (2023). STEP Clinical Trial Program. Retrieved from Novo Nordisk's official website and clinical trial registries.
[5] Ahmann, A. J., et al. (2021). Cost-effectiveness of semaglutide for type 2 diabetes: A budget impact analysis. Value in Health, 24(9), S501.
[6] Evaluate Pharma. (2023). Global Drug Forecast 2023. (Proprietary report; data cited is representative of industry analysis).
[7] GoodRx. (2024). Semaglutide Prices, Coupons, and Patient Assistance Programs. Retrieved from GoodRx.com. (Specific pricing data may vary by pharmacy and location).
[8] Jastreboff, A. M., et al. (2022). Tirzepatide once weekly for the treatment of obesity in adults with overweight or obesity: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 400(10363), 1597-1607.
[9] U.S. Food & Drug Administration. (2024). Patent and Exclusivity Database. Retrieved from FDA's Orange Book and related patent databases. (Specific patent numbers and expiry dates are subject to ongoing legal and regulatory review).
More… ↓
